188 related articles for article (PubMed ID: 22321963)
1. Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with stage 2 hypertension.
Flack JM; Yadao AM; Purkayastha D; Samuel R; White WB
J Am Soc Hypertens; 2012; 6(2):142-51. PubMed ID: 22321963
[TBL] [Abstract][Full Text] [Related]
2. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
Yarows SA; Oparil S; Patel S; Fang H; Zhang J
Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
[TBL] [Abstract][Full Text] [Related]
3. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
[TBL] [Abstract][Full Text] [Related]
5. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension.
Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Ritter S; Zhang J
Curr Med Res Opin; 2010 Dec; 26(12):2841-9. PubMed ID: 21062137
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
[TBL] [Abstract][Full Text] [Related]
8. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
9. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
11. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
Drummond W; Sirenko YM; Ramos E; Baek I; Keefe DL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):327-33. PubMed ID: 21846154
[TBL] [Abstract][Full Text] [Related]
12. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Smith B; Weissbach N; Maboudian M; Botha J; van Ingen H
Circulation; 2009 Jan; 119(3):417-25. PubMed ID: 19139391
[TBL] [Abstract][Full Text] [Related]
13. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
[TBL] [Abstract][Full Text] [Related]
14. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
[TBL] [Abstract][Full Text] [Related]
15. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
16. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing.
Hermida RC; Ayala DE; Mojón A; Fontao MJ; Fernández JR
Chronobiol Int; 2011 Aug; 28(7):601-10. PubMed ID: 21823969
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
[TBL] [Abstract][Full Text] [Related]
18. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.
Pool JL; Glazer R; Weinberger M; Alvarado R; Huang J; Graff A
Clin Ther; 2007 Jan; 29(1):61-73. PubMed ID: 17379047
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
Oparil S; Yarows SA; Patel S; Fang H; Zhang J; Satlin A
Lancet; 2007 Jul; 370(9583):221-229. PubMed ID: 17658393
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis.
Giles TD; Alessi T; Purkayastha D; Zappe D
J Clin Hypertens (Greenwich); 2012 May; 14(5):299-306. PubMed ID: 22533656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
